Mark Ralph is a seasoned leader with over 20 years of experience in the pharmaceutical and cleantech industries. He is currently the President and CEO of Axine, bringing a broad background that spans drug discovery, operations, outsourcing management, financial oversight, business development, licensing, and venture capital.

Before joining Axine, Mark held a variety of senior positions across the life sciences sector, where he played key roles in driving innovation and growth. He has also served on the boards of several digital health companies, including Wellth, xCures, and Optina Diagnostics, and previously represented Boehringer Ingelheim in a strategic fund-of-funds investment.

Mark holds a Master of Science in Chemistry from Memorial University of Newfoundland and an MBA with a concentration in Finance from the University of Connecticut.